CMR study comparing antiplatelet therapies in STEMI patients

Ticagrelor has many protective cardiovascular properties beyond potent antiplatelet action. This study aimed to compare the effects of ticagrelor versus clopidogrel on infarcted mass, quantified by cardiac magnetic resonance (CMR), in patients with ST-segment elevation acute myocardial infarction (STEMI). Adult patients of both sexes with STEMI under a pharmaco-invasive strategy were included (n=225). Patients were treated by thrombolysis within six hours of symptom onset and underwent angiography with percutaneous coronary interventions, when needed, within the first 24 hours. Prior to the invasive procedures, patients were randomly assigned to receive either ticagrelor or clopidogrel using a centralized computerized system. Patients were followed on a weekly basis to optimize their medical therapy. After 30 days, CMR was performed and a smaller percentage of left ventricular infarcted mass was found with ticagrelor (p=0.012), despite similar angiographic findings at baseline (Syntax s..., The CONSORT checklist is available as a supplementary file.
Ethics approval
The study protocol was approved by the local ethics committee (IRB 0297/2014; CAAE: 71652417.3.0000.5505), which follows the last version of the Helsinki Declaration. All patients signed the informed consent prior to any study procedure.
Study design
The comparison between ticagrelor and clopidogrel in patients with STEMI is part of a thematic study with pre-specified analyses that also included two lipid-lowering strategies. The study design, including objectives and inclusion/exclusion criteria, was previously published. Briefly, the BATTLE-AMI study (NCT02428374) is a prospective, randomized, open-label clinical trial with blinded CMR and angiographic analyses. Adult STEMI patients who underwent thrombolytic therapy were included. After providing written informed consent, eligible patients were randomized in a 1:1 ratio to receive either ticagrelor or clopidogrel using a centralized computerized system before..., # Data from: CMR study comparing antiplatelet therapies in STEMI patients

Dataset DOI: [10.5061/dryad.8pk0p2p1v](10.5061/dryad.8pk0p2p1v)

## Description of the data and file structure

CMR collected after 30 days post-STEMI

### Files and variables

#### File: Dryad_Dataset_Revised_(1)03092025.xlsx

**Description:** 

**Variables**

Gender, Age Group

Group: Study group identifier (e.g., treatment/control).

Lipid-lowering therapy: Whether the patient is on lipid-lowering medication (e.g., statins).

Antiplatelet therapy: Use of antiplatelet drugs (e.g., aspirin, clopidogrel).

Diabetes status: Diabetes classification (1 = no, 2 = type 1, 3 = type 2).

Weight: Patient’s body weight (kg).

Hypertension: Presence of high blood pressure (1 = yes, 2 = no).

Day 1 hs troponin: T High-sensitivity troponin T levels on day 1 (biomarker for cardiac injury).

Systolic blood pressure: Systolic BP (mmHg).

Diastolic blood pressure: Diastolic BP (mmHg).

Smoking status of the patient.

Heart rate:..., Data was anonymized and followed the requirements of the Ethics Committee of UNIFESP.
All patients included in the study agreed to participate in the study and signed the informed consent before any study procedure. The study was approved by the Ethics Committee of Universidade Federal de São Paulo (UNIFESP), registered as IRB 0297/2-14 CAAE: 7165417.3.0000.5505., Patients were anonymized, followed the requirements of the Ethics Committee of UNIFESP, and signed the consent form.